Emergency BU Alert Boston University's Charles River and Medical Center Campuses will be closing today, Monday, January 26, 2015 at 5:00 PM and will be closed all day Tuesday, January 27, 2015. All normal academic and administrative activities (e.g. classes, seminars and meetings) that are scheduled to take place after 5:00 PM on Monday are cancelled. When classes resume, they will resume on the regular class schedule. Whether or how classes are to be made up is at the discretion of the faculty member. For detailed information about the Boston University Medical campus, please go to http://www.bu.edu/ehs/comm Please note: Employees in essential services must report as scheduled. Essential services include, but are not limited to, University Police, Public Safety, Emergency Patient Treatment, Facilities Management and Planning, Environmental Health & Safety, University Dining Services, Mail Services, Student Health Services and the University Switchboard. For the very latest information, please go to http://www.bu.edu/today

Head & Neck

Advanced:

CIRB #H-29284/RTOG #R0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab For Locally-Advanced Resected Head and Neck Cancer

IRB #H-33141/CTSU #E3311: A Phase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer (pending IRB approval)

IRB #H-32666/RTOG #R1221: A Randomized Ph. II Trial of Transoral Endoscopic Head And Neck Surgery followed by Risk-Based IMRT and Weekly Cisplatin versus IMRT and Weekly Cisplatin for HPV Negative Oropharynx Cancer (pending IRB approval)

High Risk:

CIRB #H-32379/RTOG #R1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck Salivary Gland Tumors:

IRB #H-32124/RTOG# R1008: A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

Nasopharyngeal:

CIRB #H-33148/NRG# HN001: Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) (pending IRB approval)

Primary teaching affiliate
of BU School of Medicine